CD4 and glioblastoma: This evidence elucidates the capacity of GBM recruitment and activation of CD4+ CD56+ NKT cells is unique in comparison to the vast majority of single CD8-positive CD3+ CD56+ cells in the PBMCs of patients with GBM [32].